A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors-Reference-Cited by-同舟云学术

A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors

Published:2017-02-02 Issue:4 Volume:47 Page:298-305
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Nokihara Hiroshi¹,Yamamoto Noboru¹,Yamada Yasuhide¹,Honda Kazunori¹²,Asahina Hajime¹³,Tamura Yosuke¹⁴,Hozak Rebecca R.⁵,Gao Ling⁶,Suzukawa Kazumi⁷,Enatsu Sotaro⁷,Tamura Tomohide¹⁸

Affiliation:

1. National Cancer Center Hospital, Tokyo, Japan

2. Present address: Aichi Cancer Center Hospital, Nagoya, Japan

3. Present address: Hokkaido University Hospital, Sapporo, Japan

4. Present address: Osaka Medical College Hospital, Osaka, Japan

5. Eli Lilly and Company, Indianapolis, IN, USA

6. Eli Lilly and Company, Bridgewater, NJ, USA

7. Eli Lilly Japan, Kobe, Japan

8. Present address: St Luke's International Hospital, Tokyo, Japan

Funder

ImClone Systems

Eli Lilly and Company

ProScribe – Envision Pharma Group

K.K. ProScribe's services

Good Publication Practice

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/47/4/298/26368098/hyx008.pdf

Reference23 articles.

1. Vascular endothelial growth factor as a target for anticancer therapy;Ferrara;Oncologist,2004

2. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy;Youssoufian;Clin Cancer Res,2007

3. Clinical advances in the development of novel VEGFR2 inhibitors;Fontanella;Ann Transl Med,2014

4. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth;Hamerlik;J Exp Med,2012

5. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2;Spratlin;J Clin Oncol,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors;ESMO Open;2023-04

2. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein;Expert Opinion on Drug Safety;2021-10-28

3. Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo;Scientific Reports;2021-07-23

4. Ramucirumab: A Review in Hepatocellular Carcinoma;Drugs;2020-02

Communication Of Cancer Cells And Lymphatic Vessels In Cancer: Focus On Bladder Cancer

;OncoTargets and Therapy;2019-10